About   Help   FAQ
Mammalian Phenotype Ontology Annotations
Query Results - Summary
Symbol
Name
ID
Tnfrsf1a
tumor necrosis factor receptor superfamily, member 1a
MGI:1314884
73 phenotypes from 11 alleles in 21 genetic backgrounds
Export: Excel File
Allelic Composition
Genetic Background
Annotated Term Reference
Tnfrsf1aem1(IMPC)Ccpcz/Tnfrsf1aem1(IMPC)Ccpcz
C57BL/6NCrl-Tnfrsf1aem1(IMPC)Ccpcz/Ccpcz
abnormal heart morphology J:211773
abnormal skin morphology J:211773
enlarged heart J:211773
increased effector memory CD8-positive, alpha-beta T cell number J:211773
increased neutrophil cell number J:211773
increased NK cell number J:211773
Tnfrsf1atm1.1Gkl/Tnfrsf1a+
involves: 129/Sv * C57BL/6
increased susceptibility to induced morbidity/mortality J:92470
liver inflammation J:92470
Tnfrsf1atm1.1Gkl/Tnfrsf1atm1.1Gkl
involves: 129/Sv * C57BL/6
abnormal cytokine secretion J:92470
decreased susceptibility to bacterial infection J:92470
increased susceptibility to experimental autoimmune encephalomyelitis J:92470
increased susceptibility to induced morbidity/mortality J:92470
liver inflammation J:92470
Tnfrsf1atm1Blt/Tnfrsf1a+
involves: 129P2/OlaHsd
abnormal response/metabolism to endogenous compounds J:210950
decreased circulating interleukin-6 level J:210950
decreased susceptibility to induced morbidity/mortality J:210950
Tnfrsf1atm1Blt/Tnfrsf1atm1Blt
B6.129P2-Tnfrsf1atm1Blt
abnormal sleep pattern J:103266
impaired central nervous system regeneration J:71178
Tnfrsf1atm1Blt/Tnfrsf1atm1Blt
C.129P2-Tnfrsf1atm1Blt
decreased physiological sensitivity to xenobiotic J:87476
decreased susceptibility to xenobiotic induced morbidity/mortality J:87476
Tnfrsf1atm1Blt/Tnfrsf1atm1Blt
involves: 129/Sv * 129P2/OlaHsd * C57BL/6
decreased circulating alanine transaminase level J:50903
decreased susceptibility to bacterial infection J:50903
Tnfrsf1atm1Blt/Tnfrsf1atm1Blt
involves: 129P2/OlaHsd
abnormal response/metabolism to endogenous compounds J:210950
decreased susceptibility to induced morbidity/mortality J:210950
impaired humoral immune response J:210950
increased sensitivity to induced cell death J:210950
increased susceptibility to bacterial infection induced morbidity/mortality J:210950
Tnfrsf1atm1Blt/Tnfrsf1atm1Blt
involves: 129P2/OlaHsd * C57BL/6
abnormal immune system physiology J:14424
abnormal lymph node B cell domain morphology J:40970
abnormal Peyer's patch follicle morphology J:40970
abnormal Peyer's patch morphology J:40970
absent follicular dendritic cells J:40970
decreased IgG1 level J:115225
decreased interleukin-6 secretion J:14424
decreased Peyer's patch number J:40970
decreased susceptibility to experimental autoimmune encephalomyelitis J:115225
increased susceptibility to bacterial infection J:14424
increased susceptibility to parasitic infection J:114203
increased susceptibility to type I hypersensitivity reaction J:92307
Tnfrsf1atm1Blt/Tnfrsf1atm2Gkl
Tg(Cr2-cre)3Cgn/0
involves: 129P2/OlaHsd * 129S/SvEv
normal immune system phenotype J:113314
Tnfrsf1atm1Imx/Tnfrsf1a+
involves: C57BL/6
abnormal response/metabolism to endogenous compounds J:210950
decreased circulating interleukin-6 level J:210950
decreased susceptibility to induced morbidity/mortality J:210950
Tnfrsf1atm1Imx/Tnfrsf1atm1Imx
C57BL/6-Tnfrsf1atm1Imx
abnormal airway responsiveness J:120174, J:143836
abnormal glutamate-mediated receptor currents J:152590
abnormal nervous system physiology J:112713
abnormal neuron proliferation J:112713
abnormal oval cell physiology J:66448
abnormal respiratory mechanics J:143836
decreased inflammatory response J:45147
decreased microglial cell number J:112713
decreased susceptibility to dopaminergic neuron neurotoxicity J:78637
decreased susceptibility to endotoxin shock J:45147
decreased tumor incidence J:66448
increased circulating tumor necrosis factor level J:45147
increased skin papilloma incidence J:89088
increased susceptibility to bacterial infection J:45147
lung inflammation J:120174
Tnfrsf1atm1Imx/Tnfrsf1atm1Imx
C57BL/6-Tnfrsf1atm1Imx/J
abnormal chemokine secretion J:160543
abnormal follicular dendritic cell morphology J:160543
abnormal macrophage physiology J:160543
decreased circulating interleukin-6 level J:160543
decreased interleukin-6 secretion J:160543
decreased susceptibility to endotoxin shock J:160543
decreased susceptibility to induced morbidity/mortality J:160543
increased circulating tumor necrosis factor level J:160543
Tnfrsf1atm1Imx/Tnfrsf1atm1Imx
involves: 129S7/SvEvBrd * C57BL/6
abnormal immune system physiology J:45147
Tnfrsf1atm1Imx/Tnfrsf1atm1Imx
involves: C57BL/6
abnormal response/metabolism to endogenous compounds J:210950
decreased susceptibility to induced morbidity/mortality J:210950
impaired humoral immune response J:210950
increased sensitivity to induced cell death J:173568
increased susceptibility to bacterial infection induced morbidity/mortality J:210950
Tnfrsf1atm1Mak/Tnfrsf1a+
involves: 129S2/SvPas
abnormal response/metabolism to endogenous compounds J:210950
decreased circulating interleukin-6 level J:210950
decreased susceptibility to induced morbidity/mortality J:210950
Tnfrsf1atm1Mak/Tnfrsf1atm1Mak
involves: 129S2/SvPas
abnormal response/metabolism to endogenous compounds J:210950
abnormal spleen germinal center morphology J:139030
decreased circulating interleukin-6 level J:138824
decreased IgG level J:139030
decreased susceptibility to bacterial infection J:4753, J:121930
decreased susceptibility to induced morbidity/mortality J:210950
impaired humoral immune response J:210950
impaired skin barrier function J:59056
increased bone mineral density J:135519
increased circulating tumor necrosis factor level J:139030
increased sensitivity to induced cell death J:210950
increased susceptibility to bacterial infection induced morbidity/mortality J:4753, J:139030, J:210950
Tnfrsf1atm1Mak/Tnfrsf1atm1Mak
involves: 129S2/SvPas * C57BL/6J * DBA/2J
granulomatous inflammation J:55889
Tnfrsf1atm1Mak/Tnfrsf1atm1Mak
involves: 129S2/SvPas * C57BL/6J * NOD
decreased susceptibility to autoimmune diabetes J:64051
Tnfrsf1atm1Rsie/Tnfrsf1a+
B6.Cg-Tnfrsf1atm1Rsie
impaired adaptive thermogenesis J:160543
increased circulating tumor necrosis factor level J:160543
increased interleukin-6 secretion J:160543
increased susceptibility to endotoxin shock J:160543
increased susceptibility to induced morbidity/mortality J:160543
Tnfrsf1atm1Rsie/Tnfrsf1atm1Rsie
B6.Cg-Tnfrsf1atm1Rsie
abnormal chemokine secretion J:160543
abnormal follicular dendritic cell morphology J:160543
abnormal macrophage physiology J:160543
decreased circulating interleukin-1 beta level J:160543
decreased circulating interleukin-6 level J:160543
decreased interleukin-6 secretion J:160543
decreased susceptibility to endotoxin shock J:160543
decreased susceptibility to induced morbidity/mortality J:160543
increased circulating tumor necrosis factor level J:160543
Tnfrsf1atm2.1Rsie/Tnfrsf1a+
B6.Cg-Tnfrsf1atm2.1Rsie
abnormal macrophage physiology J:160543
decreased circulating interleukin-1 beta level J:160543
decreased circulating interleukin-6 level J:160543
decreased interleukin-6 secretion J:160543
increased interleukin-6 secretion J:160543
increased susceptibility to endotoxin shock J:160543
increased susceptibility to induced morbidity/mortality J:160543
Tnfrsf1atm2.1Rsie/Tnfrsf1a+
involves: 129S6/SvEvTac
increased susceptibility to endotoxin shock J:160543
increased susceptibility to induced morbidity/mortality J:160543
Tnfrsf1atm2.1Rsie/Tnfrsf1atm2.1Rsie
B6.Cg-Tnfrsf1atm2.1Rsie
abnormal chemokine secretion J:160543
abnormal macrophage physiology J:160543
decreased circulating interleukin-6 level J:160543
decreased interleukin-6 secretion J:160543
decreased susceptibility to endotoxin shock J:160543
decreased susceptibility to induced morbidity/mortality J:160543
increased circulating tumor necrosis factor level J:160543
Tnfrsf1atm2b(EUCOMM)Wtsi/Tnfrsf1atm2b(EUCOMM)Wtsi
C57BL/6N-Tnfrsf1atm2b(EUCOMM)Wtsi/H
decreased circulating calcium level J:211773
decreased monocyte cell number J:211773
decreased neutrophil cell number J:211773
increased basophil cell number J:211773
increased eosinophil cell number J:211773
increased grip strength J:211773
increased large unstained cell number J:211773
increased leukocyte cell number J:211773
increased lymphocyte cell number J:211773
Tnfrsf1atm2Gkl/Tnfrsf1a+
Tg(Vil1-cre)997Gum/0
involves: 129S/SvEv * C57BL/6J * SJL
abnormal intestine physiology J:210950
increased susceptibility to induced morbidity/mortality J:210950
Tnfrsf1atm3.1Gkl/Tnfrsf1a+
Tg(Vil1-cre)997Gum/0
involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J * SJL
abnormal response/metabolism to endogenous compounds J:210950
decreased susceptibility to induced morbidity/mortality J:210950
Tnfrsf1atm3.1Gkl/Tnfrsf1atm3.1Gkl
Tg(Vil1-cre)997Gum/0
involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J * SJL
abnormal response/metabolism to endogenous compounds J:210950
decreased susceptibility to induced morbidity/mortality J:210950
Tnfrsf1atm4.1(TNFRSF1A)Gkl/Tnfrsf1a+
involves: 129P2/OlaHsd
decreased susceptibility to induced morbidity/mortality J:210950
tumor regression J:210950

Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support.
last database update
04/23/2024
MGI 6.23
The Jackson Laboratory